Imperial College London
Portrait Picture

MrPaulRogers

Faculty of Medicine, Department of Infectious Disease

Research Technician
 
 
 
//

Contact

 

+44 (0)20 7594 0977paul.rogers CV

 
 
//

Location

 

258 Shattock Lab.Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rogers:2002:10.1002/ijc.10132,
author = {Rogers, PM and Beale, PJ and Al-Moundhri, M and Boxall, F and Patterson, L and Valenti, M and Raynaud, F and Hobbs, S and Johnston, S and Kelland, LR},
doi = {10.1002/ijc.10132},
journal = {Int J Cancer},
pages = {858--863},
title = {Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.},
url = {http://dx.doi.org/10.1002/ijc.10132},
volume = {97},
year = {2002}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The effect of overexpressing the antiapoptotic protein BclXL in a human ovarian carcinoma cell line has been investigated in terms of sensitivity to the 2 major drugs used to treat this disease, paclitaxel and cisplatin. Stable transfection of BclXL into CH1 cells, which are relatively sensitive to cisplatin, resulted in around 2.7-fold higher expression in comparison with empty vector controls. However, this level of overexpression did not result in significant resistance in vitro to paclitaxel or cisplatin at the 50% inhibition level, using either short-term (4-day) growth inhibition or longer term colony-forming assays. By contrast, parallel subcutaneous xenograft models of these isogenic ovarian carcinoma cells in vivo, differing only in BclXL status, showed that this low-level BclXL overexpression conferred significant resistance to both paclitaxel and cisplatin in comparison with parent, nontransfected tumours. Whereas parent non-BclXL transfected tumours were highly responsive, with the disappearance of tumours for at least 50 days post treatment, tumours overexpressing BclXL grew back after 30 and 20 days after treatment with paclitaxel and cisplatin, respectively. These differences in responsiveness to paclitaxel in vivo were not attributable to any significant changes in the delivery of drug to the tumour. These data suggest that the responsiveness of ovarian cancer to paclitaxel and cisplatin in vivo, and therefore perhaps clinically, is influenced by levels of the antiapoptotic protein BclXL. Such effects may be missed in vitro when using short-term growth inhibition or clonogenic assays.
AU  - Rogers,PM
AU  - Beale,PJ
AU  - Al-Moundhri,M
AU  - Boxall,F
AU  - Patterson,L
AU  - Valenti,M
AU  - Raynaud,F
AU  - Hobbs,S
AU  - Johnston,S
AU  - Kelland,LR
DO  - 10.1002/ijc.10132
EP  - 863
PY  - 2002///
SN  - 0020-7136
SP  - 858
TI  - Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.
T2  - Int J Cancer
UR  - http://dx.doi.org/10.1002/ijc.10132
UR  - https://www.ncbi.nlm.nih.gov/pubmed/11857368
VL  - 97
ER  -
Download